Posted by Michael Wonder on 30 Apr 2023
Teva and MedinCell announce FDA approval of Uzedy (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia in adults
28 April 2023 - In a Phase 3 clinical trial, Uzedy demonstrated up to 80% reduction in risk of schizophrenia relapse versus placebo.
Teva Pharmaceuticals and MedinCell announced today that the US FDA has approved Uzedy (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults.
